Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP: MCL4001) in Patients with Relapsed or Refractory Mantle Cell Lymphoma

被引：0
|
作者：
Martin, Peter [1 ]
Goy, Andre [2 ]
Ramchandren, Radhakrishnan [3 ]
Ferrante, Lucille [4 ]
Reddy, Vijay [4 ]
Londhe, Anil [4 ]
Wildgust, Mark [5 ]
McGowan, Tracy [4 ]
Bartlett, Nancy L. [6 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Janssen Sci Affairs LLC, Horsham, PA USA
[5] Janssen Global Serv, Raritan, NJ USA
[6] Washington Univ, Sch Med, St Louis, MO USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial
    Ferrero, S.
    Pastore, A.
    Scholz, C. W.
    Forstpointner, R.
    Pezzutto, A.
    Bergmann, L.
    Truemper, L.
    Finke, J.
    Keller, U.
    Ghione, P.
    Passera, R.
    Hiddemann, W.
    Weigert, O.
    Unterhalt, M.
    Dreyling, M.
    LEUKEMIA, 2016, 30 (04) : 984 - 987
  • [22] Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory (R/R) and Treatment-Naive (TN) Mantle Cell Lymphoma (MCL)
    Lakhotia, Rahul
    Pittaluga, Stefania
    Phelan, James
    Yang, Yandan
    Davies-Hill, Theresa
    Simard, Jillian
    Muppidi, Jagan
    Huang, Da Wei
    Thomas, Craig
    Ceribelli, Michele
    Tosto, Frances
    Pradhan, Amynah
    Juanitez, Anna
    Rimsza, Lisa
    Jacob, Allison
    Simmons, Heidi
    Steinberg, Seth
    Jaffe, Elaine
    Staudt, Louis
    Roschewski, Mark
    Wilson, Wyndham
    Melani, Christopher
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S461 - S461
  • [23] Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
    Wang, Michael
    Schuster, Stephen J.
    Phillips, Tycel
    Lossos, Izidore S.
    Goy, Andre
    Rule, Simon
    Hamadani, Mehdi
    Ghosh, Nilanjan
    Reeder, Craig B.
    Barnett, Evelyn
    Bravo, Marie-Laure Casadebaig
    Martin, Peter
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2017, 10
  • [24] Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)
    Michael Wang
    Stephen J. Schuster
    Tycel Phillips
    Izidore S. Lossos
    Andre Goy
    Simon Rule
    Mehdi Hamadani
    Nilanjan Ghosh
    Craig B. Reeder
    Evelyn Barnett
    Marie-Laure Casadebaig Bravo
    Peter Martin
    Journal of Hematology & Oncology, 10
  • [25] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [26] Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study
    Wang, Michael
    Martin, Peter
    Phillips, Tycel
    Goy, Andre
    Lossos, Izidore S.
    Rule, Simon A.
    Hamadani, Mehdi
    Ghosh, Nilanjan
    Reeder, Craig B.
    Barnett, Evelyn
    Bravo, Marie-Laure Casadebaig
    Schuster, Stephen J.
    BLOOD, 2016, 128 (22)
  • [27] REAL-WORLD TREATMENT OUTCOMES AMONG RELAPSED/REFRACTORY PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH IBRUTINIB OR ACALABRUTINIB
    Crawford, S.
    Lafeuille, M. H.
    Emond, B.
    Harb, D.
    Voladarsky, R.
    Chen, N.
    Karve, S.
    VALUE IN HEALTH, 2023, 26 (06) : S403 - S403
  • [28] Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma
    Crusoe, Edvan de Queiroz
    Fernandes Pimenta, Flavia Cristina
    Maiolino, Angelo
    de Castro, Nelson Siqueira
    Pei, Huiling
    Trufelli, Damila
    Fernandez, Mariana
    Herriot, Luciana Barreto
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2021, 43 (04) : 417 - 423
  • [29] Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
    Wang, Michael
    Jurczak, Wojciech
    Trneny, Marek
    Belada, David
    Wrobel, Tomasz
    Ghosh, Nilanjan
    Keating, Mary-Margaret
    van Meerten, Tom
    Alvarez, Ruben Fernandez
    von Keudell, Gottfried
    Thieblemont, Catherine
    Peyrade, Frederic
    Andre, Marc
    Hoffmann, Marc
    Glusman, Edith Szafer
    Lin, Jennifer
    Dean, James P.
    Neuenburg, Jutta K.
    Tam, Constantine S.
    BLOOD, 2023, 142
  • [30] MCL-002: UPDATED EFFICACY AND SAFETY RESULTS FOR LENALIDOMIDE VSINVESTIGATOR'S CHOICE MONOTHERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Arcaini, L.
    Rule, S.
    Lamy, T.
    Walewski, J.
    Belada, D.
    Mayer, J.
    Radford, J.
    Jurczak, W.
    Morschhauser, F.
    Alexeeva, J.
    Biyukov, T.
    Patturajan, M.
    Bravo, M. L. Casadebaig
    Trneny, M.
    HAEMATOLOGICA, 2016, 101 : 476 - 476
12345